Video

Dr. Tagawa on treatment patterns and survival in mCSPC

Author(s):

Urology Times staff
Conference|ESMO Annual Congress

Scott T. Tagawa, MD, discusses the background and results of the study, “Treatment patterns and overall survival in metastatic castration-sensitive prostate cancer from 2006 to 2019,” which was presented during the 2021 ESMO Congress.

Tagawa is a professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.

Related Videos
Related Content
Conference Preview: American Urological Association 2025
April 23rd 2025

Conference Preview: American Urological Association 2025

Hannah Clarke
View slated interviews with experts as well as insights from urologists on what to watch for.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Welcome to Fabulous Las Vegas Neon Sign | Image Credit: © somchaij - stock.adobe.com
April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke
We preview several noteworthy P2 presentations in the urologic oncology space.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor
“Among active surveillance patients, 82% are metastases-free, and 60% were metastases-free and had an intact, unradiated bladder,” said Pooja Ghatalia, MD.
Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC
February 18th 2025

Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC

Hannah Clarke
However, the triplet regimen did not lead to an improvement in overall survival.
© 2025 MJH Life Sciences

All rights reserved.